Neurotez Inc.:

Innovative solutions for brain disorders

A vibrant company with unparalleled talent and capabilities to transform Alzheimer’s disease.

Neurotez

Memtin™

Our patented hormone replacement therapy for slowing cognitive decline in Alzheimer's disease and other dementias

"Our flagship and a personal commitment"

Nikolaos Tezapsidis, President & CEO

Neurotez



A Devastating Unmet Medical Need

A Very Promising Solution

MEMTIN™ (Leptin) for Cognitive Decline

- Ten years of in vitro and in vivo pre-clinical studies (*Neurotez*)
- Retrospective (*including Neurotez's*) and prospective human studies and a few anecdotal interventional human studies

Support a role of Leptin in:

- Neuroprotection,
- Cognitive enhancement,
- Decreasing levels of phospho-tau/tau,
- Decreasing beta amyloid (Aβ) and is associated with lower risk for dementia in elderly

Leptin as Replacement Therapy

- A relatively de-risked multi-functional preventative and therapeutic approach for cognitive decline due to Alzheimer's and optimally for early stage (prodromal AD) hypoleptinimics.
- Several novel use patents in prominent markets and Biologics Act protection
- Derisked 505(b)(2) path to Phase 2
- Targeted phenotypic and genotypic selection of patients

Novel, Differentiating

MEMTIN™

- Alzheimer's disease as diabetes of the brain or Type III diabetes
- A natural protein with procognitive properties at Low levels in Alzheimer's (AD) with known Safety Profile (Effectively Phase II ready)
- Ameliorates both Abeta and tau pathologies, upstream molecular target related to metabolism
- Clinical Strategy involving enrichment of patients, targeting patient group most likely to respond

PREVIOUS FAILURES

- Antibodies directed against Abeta or tau are difficult to penetrate into the brain and are toxic at the high doses needed for efficacy
- Heterogeneity in patient groups and targeting late stage AD patients
- Wrong targets (Abeta and/or tau may be biomarkers, not culprits

Drug Development Path for Memtin™ (Leptin): Key Milestones



Experienced Management Team

Nikolaos Tezapsidis, PhD, *Chairman, Chief Executive Officer & President*
18+ years experience in biomedical research; Two awards from the Alzheimer's Association Fellow of the Science and Engineering Council and the Wellcome Trust

Hamish McArthur, PhD, *Manufacturing Chief Officer,*
Executive with 33 years biologics experience within Pfizer, directly involved in numerous approved products.

J. Wesson Ashford, MD, PhD, *Chief Medical Officer Clinical Professor (affiliated),* Department of Psychiatry & Behavioral Sciences, Stanford University, Scientific Advisory Board Member and Chair of the Memory Screening Advisory Committee of the Alzheimer's Foundation of America.



Jukka Karjalainen, MD, PhD, *Chief Operating Officer.*
Experience in pharmaceuticals and medical devices and clinical drug development from Phase I to Phase IV

James Harris, MBA, *Chief Financial Officer*
20+ years experience in startups, licensing and biosimilars.

Jane Johnston, PhD, *VP of Operations*
18+ years of research in cellular neuroscience

Board of Directors & Advisors

Directors

Nikolaos Tezapsidis, PhD (Chair)
Neurotez

J Wes Ashford, MD, PhD
Stanford U/ Neurotez

James Harris III, MBA
Healthcare Economics /Neurotez

Thomas J Humphries, MD

36 years of experience in Pharma and Biotech; 225+ papers published; Retired as a Colonel after 26 years in the Navy and Airforce

Bob Oliver, MBA

MBA in Marketing from the Haub School of Business at Saint Joseph's University; President and CEO of Otsuka America Pharmaceutical, Inc.; VP and Global Business Manager for Oncology at Wyeth

Advisors

Julio Licinio, MD, FRANZCP
SVP and Dean at SUNY

Arthur Klausner, MBA
Director at Monopar Therapeutics

Steven Jacobsen, PhD
CEO at ALSP Inc

Daniel P. van Kammen, MD, PhD
CNS Pharma

Gil Block, MD
CMO at Neuraltus, Inc

Robert Winkler, MD
CMO at Stealth Biotech

Kent Iverson, BS
Pharmaceutical Advisors

Lex Van der Ploeg, PhD
CSO at Rhythm Pharma

Forward-Looking Statement

Our discussion may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout presentation, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent SEC filings for a more complete discussion of these factors and other risks, particularly under the heading “Risk Factors.”

Service Providers

Corporate Lawyer

- Ernest Stern

Culhane Meadows
5008 Scarsdale Road
Bethesda, MD 20816

CPA Firms

2020

- Joel Liebman
  Liebman Goldberg & Hymowitz, LLP
  595 Stewart Avenue – Suite 420
  Garden City, NY 11530

2021

- Jason M. Tyra, CPA, PLLC 1700 Pacific Avenue, Suite 4710 l Dallas, TX 75201

Bank

- Santander Bank

Bank Address: Santander Bank, N.A.,601 Penn Street, Reading, PA 19601

Beneficiary: Neurotez Inc.

SUMMARY

- Repurposing MYALEPT, an approved drug, as **Memtin™**
- Team: Top-Notch Leaders in Academia and Pharmaceutical Industry
- Drug is an endogenous protein naturally transported into the brain with receptors in the hippocampus (area affected by disease)
- Data from thousands of patients supporting an association of the drug to protection against Alzheimer's
- Data from preclinical studies demonstrating efficacy as a disease modification entity
- Perfectly positioned to allow early intervention and prevention therapy for those at risk (because of its safety profile)
- Novel use patents issued in US, Japan, China, Australia, S Africa and have pending in Europe, Canada and India, protection until 2029
- Drug as a biologic, will get 12 y of market exclusivity from approval in the US (similar provisions ex-US)
- Drug can be produced cost-effectively and in large batches in Ecoli
- Treatment will be combined with diagnostic tests (plasma leptin)/apoE4)
- Can be subject to accelerated approval, using protein as a surrogate marker as an endpoint, can cut clinical development costs by 10s of $millions and time by 3-4 years.

Nikolaos Tezapsidis
President & CEO
Neurotez, Inc.
991 Highway 22, Suite 200A,
Bridgewater, NJ 08807, USA
Tel:+1-908-998-1340
Fax: +1-908-864-8957
ntezapsidis@neurotez.com
Website: http://neurotez.com

Neurotez Inc.:

APPENDIX

Studies: Serum Leptin Levels in Elderly and Prognosis

In elderly, higher serum Leptin is associated with a lower risk for Alzheimer's disease and dementia

Lieb et al, JAMA, 2009



For BMI<25, patients with AD have lower serum Leptin levels compared to patients with Vascular Dementia (VaD)

Power et al, Dementia, 2001



Studies: Leptin Targets Amyloid Beta and Tau Protein

Amyloid Plaques

- Inhibition of amyloid beta (Aβ)
- Up-regulation of Aβ uptake
- Reduction of brain levels of Aβ
- Reduction of plaque density

Neurofibrillary Tangles

- Reduction of phosphorylation of tau protein in vitro and in vivo
- Phosphorylation of tau protein precedes the formation of neurofibrillary tangles





Studies: Leptin Improves Memory in AD Animal Models

Animal studies: Behavioral (CRND8)

Studies: Direct Evidence for a Causation

Cognitive benefits in humans: treating leptin deficiency in adults and young"

- Behavioral changes after 2 wks, Licinio et al (2004)
- Leptin Replacement increases Gray matter concentration in Leptin (-) adults, Matochik et al (2005)
- Plasticity of Gray Matter changes following Leptin discontinuation / reinitiation in Leptin (-) adults, London et al (2011)
- Leptin Replacement improves Cognitive Development in Leptin (-) young, Paz-Filho et al (2008)

(Licinio's interventional clinical studies)



Studies: Serum Leptin Levels in MCI

Approximately 70% of MCI Subjects Have Plasma Leptin Values Lower than the Median Leptin Value of Normal Elderly.

(Neurotez)





See attached documents